Stocks and Investing Stocks and Investing
Tue, July 26, 2011
[ Tue, Jul 26th 2011 ] - Market Wire
CytRx Announces Public Offering

EXACT SCIENCES CORP (NASDAQ:EXAS), Up By 6.25% ($0.55) From $8.800 After BUYINS.NET Report Predicted Strength Before Earnings


Published on 2011-07-26 05:21:28 - WOPRAI
  Print publication without navigation


July 26, 2011 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Tuesday, July 12th 2011 stating that EXACT SCIENCES CORP (NASDAQ:EXAS) was expected to be Up Before its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=exas&id=177820

At the time this story was written, EXACT SCIENCES CORP (NASDAQ:EXAS) is Up By 6.25% ($0.55) From $8.800 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

EXACT SCIENCES CORP (NASDAQ:EXAS) - Exact Sciences Corporation, a molecular diagnostics company, focuses on the early detection and prevention of colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Its non-invasive stool-based DNA (sDNA) screening technology includes proprietary and patented methods that isolate and analyze human deoxyribonucleic acid (DNA) present in stool to screen for the presence of colorectal pre-cancer and cancer. The companys principal product includes ColoSure, a non-invasive stool-based DNA testing service for the detection of colorectal cancer in the average-risk population. Exact Sciences Corporation has a strategic alliance with LabCorp; a collaboration, license, and purchase agreement with Genzyme Corporation; and a licensing and research agreement with the MAYO Foundation for Medical Education and Research. The company was founded in 1995 and is headquartered in Madison, Wisconsin.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. EXACT SCIENCES CORP (NASDAQ:EXAS) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net